Vaxzevria (ChAdOx1-S recombinant) / University of Oxford, Emergent Biosolutions, Jenner Institute, Barinthus Bio, AstraZeneca - LARVOL DELTA

One-year antibody kinetics and effectiveness of a BNT162b2 booster after four primary COVID-19 vaccination regimens in Mongolia. (PubMed, Vaccine) - "A BNT162b2 booster following diverse primary COVID-19 vaccination regimens induced strong humoral responses that declined over 12 months and showed an acceptable reactogenicity profile. VE against SARS-CoV-2 infection was highest soon after boosting and lower later in follow-up. Although antibody levels and VE showed similar temporal patterns, these findings should be interpreted as complementary outcomes rather than evidence of a direct causal relationship or a formal immunological correlate of protection."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Long-COVID syndrome and vaccination protection – a prospective study analysis (ERS 2026) - "Most of the individuals received two doses (58.5%), predominantly Comirnaty® (Pfizer), followed by Vaxzevria® (AstraZeneca)...No significant differences were observed with fatigue, however, lower scores were seen with with Janssen® alone (mean 9.0) and Janssen® plus Spikevax® (Moderna) (mean 9.5), whereas Pfizer regimens showed higher scores (mean 22). Our study supports the effectiveness of the vaccine protecting against acute infection severity, but it also shows a tendency in reducing respiratory symptom burden in Long-COVID, reinforcing its protective role beyond the acute phase."

Clinical • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Atypical Intracerebral Hemorrhage With a Fatal Outcome Following the ChAdOx1 nCoV-19 Vaccine. (PubMed, Cureus) - "This case is characterized by several atypical features, including fatal ICH occurring within a compatible timeframe following vaccination, in the absence of thrombocytopenia, coagulation abnormalities, or evidence of vaccine-induced immune thrombotic thrombocytopenia. It highlights the heterogeneity of neurological events occurring after vaccination and the importance of continued pharmacovigilance."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombocytopenia

Assessment of the immune response induced by ChAdOx1 nCoV-19 Oxford-AstraZeneca, Sputnik V, and BNT162b2 Pfizer-BioNTech vaccines during the COVID-19 epidemic outbreak in the Mexican population: Gene expression of the cytokine storm. (PubMed, Infect Genet Evol) - "Longitudinal studies with appropriate controls are needed to establish the biological significance of these transcriptional patterns."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD79A • FCGR3A • IL10 • IL2

Safe prolonged prophylactic use and tolerability of Ashwagandha following COVISHIELD™ vaccination over 24 weeks: a multicentre randomized double-blind placebo-controlled trial. (PubMed, Front Med (Lausanne)) - "Further research is required. http://www.clinicaltrials.gov/, identifier CTRI/2021/06/034496."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Long-term adverse effects following COVID-19 vaccination: A comparative analysis of Oxford AstraZeneca, Pfizer-BioNTech, and Moderna vaccines. (PubMed, Medicine (Baltimore)) - "This study aimed to investigate long-term adverse clinical symptoms following COVID-19 vaccination with the Oxford AstraZeneca (ChAdOx1 nCoV-19, Oxford), Pfizer-BioNTech (BNT162b2), and Moderna (mRNA-1273) vaccines. In conclusion, the most commonly reported long-term adverse effects after COVID-19 vaccination were chronic fatigue, cognitive impairment, and menstrual irregularity. Further large-scale studies are required to provide more conclusive evidence."

Clinical • Journal • Alzheimer's Disease • Cognitive Disorders • Fatigue • Infectious Disease • Novel Coronavirus Disease • Women's Health

Subacute-Onset Anemia Following COVID-19 Vaccine Combination with ChAdOx (AstraZeneca) and BNT162b2 (BioNTech, Pfizer)-A Case Report. (PubMed, Reports (MDPI)) - "Case Presentation: We report the case of an 80-year-old male who developed subacute-onset severe normocytic anemia with reticulocytopenia and mild leukopenia following heterologous COVID-19 vaccination with ChAdOx1 nCoV-19 (AstraZeneca) and BNT162b2 (Pfizer-BioNTech). This case suggests that, in rare instances, COVID-19 vaccination may be temporally associated with transient suppression of erythropoiesis. Further studies are required to elucidate underlying mechanisms and to guide diagnosis and management."

Journal • Anemia • Aplastic Anemia • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukopenia • Myelodysplastic Syndrome • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Thrombocytopenia

Differential functional immune recall across homologous and heterologous COVID-19 vaccination regimens. (PubMed, Front Immunol) - "Participants initially received BNT162b2, ChAdOx1 nCoV-19, or CoronaVac as the primary vaccination series, followed by either a homologous booster or a heterologous BNT162b2 booster (ChAdOx1 nCoV-19/BNT162b2 and CoronaVac/BNT162b2)...Different vaccination regimens were associated with distinct long-term cellular immune profiles under real-world conditions, with both homologous BNT162b2 and heterologous CoronaVac/BNT162b2 vaccination regimens maintaining robust memory B cell signatures and functional recall responses. The results highlight how priming combinations shape the durability and quality of immune memory, supporting the potential utility of mixed-platform booster strategies for sustaining long-term immunity."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL15 • IL6 • IL9 • TNFA

Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant. (PubMed, Vaccine) - "Reliable evidence on COVID-19 vaccine effectiveness during the period of Omicron variant predominance was essential to inform global vaccination strategies...Weekly searches covering seven databases up to 31 December 2022 sought evidence for WHO-approved vaccine platforms, including mRNA vaccines (BNT162b2, mRNA-1273), adenoviral vector vaccines (ChAdOx1-S, SII-ChAdOx1 nCoV-19, Ad26.COV2·S, Gam-COVID-Vac) and inactivated virus vaccines (CoronaVac, BBV-152)...Most results were judged to be at moderate risk of bias (361, 18%) or at serious risk of bias (1591, 78%) with the principal concern being confounding. We discuss implications for future pandemic preparedness, including the importance of standardized study protocols; robust data linkage between vaccination, testing and outcomes; and validated risk-of-bias frameworks for diverse observational designs."

Journal • Observational data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Posterior Circulation Ischemic Stroke Occurring After ChAdOx1 nCoV-19/AZD1222 Vaccination Without Evidence of Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Case Report and Focused Narrative Review. (PubMed, J Clin Med) - " This case highlights an early posterior circulation ischemic stroke temporally associated with ChAdOx1 nCoV-19/AZD1222 vaccination in the absence of VITT. Although individual causality cannot be established from a single case, careful reporting of such presentations may improve clinical recognition, etiological evaluation, and pharmacovigilance."

Journal • Review • Cardiovascular • Hematological Disorders • Hypertension • Infectious Disease • Ischemic stroke • Novel Coronavirus Disease • Respiratory Diseases • Thrombocytopenia

The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults. (PubMed, Vaccine) - "All vaccines boosted humoral immunity and had acceptable reactogenicity profiles. Higher binding and neutralising antibody responses were observed in people primed with BNT162b2."

Journal • Infectious Disease • Novel Coronavirus Disease

Rhino-Orbital Mucormycosis Following COVID-19 Viral Vector Vaccination in an Immunocompetent Patient. (PubMed, J Fungi (Basel)) - "We report a severe case in a previously healthy 44-year-old immunocompetent man who developed acute left-sided exophthalmos, ophthalmoplegia, severe visual loss, and systemic deterioration 10 days after AZD1222 COVID-19 vaccination. Clinical and radiologic findings suggested invasive rhino-orbital fungal disease, prompting immediate liposomal amphotericin B, broad-spectrum antibiotics, urgent endoscopic sinus surgery, and repeated orbital-sinonasal debridements with amphotericin B irrigation...Therapy was later adjusted to include isavuconazole and antibacterial coverage for persistent inflammation and secondary colonization...Although causality with vaccination cannot be established, the temporal association and biological plausibility warrant further investigation. Early suspicion and prompt combined medical-surgical management are essential in rapidly progressive orbital cellulitis."

Journal • Dermatology • Diabetes • Infectious Disease • Inflammation • Metabolic Disorders • Novel Coronavirus Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology • Respiratory Diseases

Assessment of Neutralizing Antibodies Against COVID-19: The Impact of Vaccination in Western Rajasthan. (PubMed, Indian J Clin Biochem) - "Covishield produces higher vaccine-induced IgG antibodies than Covaxin. BCG-vaccinated individuals show higher COVID-19 neutralizing antibodies post-vaccination."

Journal • Infectious Disease • Novel Coronavirus Disease

Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in Pakistan. (PubMed, Vaccine) - "Fractional BNT162b2 doses were non-inferior to the full Sinovac dose, but not to the full BNT162b2 dose in any priming group. Given these findings and considering the need for further research on antibody thresholds to fully understand the protection provided by fractional doses, we recommend using full BNT162b2 doses as boosters for those primed with Sinovac. If full BNT162b2 doses are not available, fractional BNT162b2 doses may be considered, but another Sinovac dose should be avoided."

Clinical • Head-to-Head • Journal • P4 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses. (PubMed, Vaccine) - "Although no emergent safety signals were detected, continued post-marketing surveillance remains imperative, particularly for neurological disorders."

Journal • CNS Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Comparative analysis of non-clinical and clinical safety assessment of COVID 19 vaccines. (PubMed, Regul Toxicol Pharmacol) - "Five authorized vaccines were included in the analysis: tozinameran (Comirnaty®), elasomeran (Spikevax®), ChAdOx1-S (Vaxzevria®), Ad26.COV2-S (Jcovden®), and the SARS-CoV-2-S protein with Matrix-M (Nuvaxovid®). These rare events were not predicted by non-clinical studies as expected. While non-clinical studies currently meet regulatory safety requirements, their predictive capacity could be enhanced by integrating a reactogenicity scoring system, harmonizing biomarker monitoring, and adding targeted parameters based on clinical evidence."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • Thrombocytopenia

Variations in cross-neutralizing reactivity is dependent on mutations on immunogenic epitopes in the spike protein of SARS-CoV-2 variants. (PubMed, Indian J Med Microbiol) - "COVISHIELD induced antibodies effectively neutralized original Wuhan strain but showed reduced neutralization against Delta and Omicron due to mutations in specific epitopes within their spike proteins. Mutations in variant specific epitopes can lead to evasion of the virus, emphasizing the importance of targeting linear region epitopes as critical binding sites."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Potential association of cluster headache with certain COVID-19 vaccines: An assessment from the pharmacovigilance databases. (PubMed, Headache) - "Our study supports the possibility of a potential association between COVID-19 vaccines and cluster headache through an updated pharmacovigilance analysis. The signal appears to be more pronounced with the Vaxzevria vaccine."

Adverse events • Journal • CNS Disorders • Infectious Disease • Migraine • Novel Coronavirus Disease • Pain • Respiratory Diseases

From Capsid to Clot: A Novel Biophysical Mechanism Driving Shear-Dependent Platelet Aggregation by ChAdOx1 nCoV-19 Vaccine (ISTH 2026) - "Table or Figure Upload (2) PRP and recombinant VWF protein perfusion over ChAdOx1-coated microfluidic post channel. DOI*10.1016/j.rpth.2026.103492"

Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombocytopenia • Thrombosis

COVID-19 Vaccine-triggered Relapsing Immune Dysregulation: An Observational Study with Four-year Follow-up. (PubMed, Ann Neurosci) - "The association between neurological manifestations of Covishield and Covaxin showed no statistically significant difference in neurological sequelae (χ 2 = 0.0466; p = .8). The association is an observation-based postulate that needs a longer, larger follow-up. As per this study, it is non-fatal and remits permanently."

Journal • Observational data • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Multiple Sclerosis • Novel Coronavirus Disease • Ocular Inflammation • Ophthalmology • Optic Neuritis • Rheumatology • Solid Tumor • Ulcerative Colitis

Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh. (PubMed, Vaccines (Basel)) - "Heterologous boosting strategies, particularly those involving mRNA vaccines, elicit stronger and more sustained IgG responses compared to a homologous booster. However, antibody waning after the second booster highlights the need for continued monitoring and potential additional vaccine strategies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Minor differences in the untranslated regions of measles vector additional transcription units are reflected by differential immunogenicity of encoded MERS-CoV Spike antigen. (PubMed, J Virol) - "Besides mRNA vaccines, also viral platform technologies, that is, the adenovirus-derived vaccines Vaxzevria and JCOVDEN, have proven to be of immense value during the COVID-19 pandemic...This knowledge allows the tailoring of vaccine vectors to fit specific target product profiles, for example, to build vectors which trigger an accentuated T cell or, alternatively, antibody response against an antigen of interest. Our study using the live-attenuated measles vaccine backbone as a promising example is therefore crucial in demonstrating that very minor differences in the vaccine backbone can alter the antigen expression profile of the vector-antigen system and impact the relative induction of T-cell or antibody responses against the added target antigen."

Journal • Infectious Disease • Measles • Novel Coronavirus Disease • Respiratory Diseases • IFNAR1

Critical Path to First-in-Human Batches of ChAdOx Vectors, Including for Emergency Response. (PubMed, Vaccines (Basel)) - " We describe experience of these stages in the production of the first GMP batches for multiple adenovirus-vectored candidates and the adaptations made for ChAdOx1 nCoV-19 (the Oxford COVID-19 vaccine) in early 2020... We discuss opportunities for additional time savings in the future. This work demonstrates suitability of an adenovirus platform to contribute to the "100 Days Mission" for vaccines against "Disease X"."

First-in-human • Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Decoupling reactogenicity from efficacy enables safer mRNA vaccines, AAV gene delivery, and in vivo base editing (ASGCT 2026) - "Cells were exposed to mRNA/lipid nanoparticle (LNP) formulations, adenoviral vectors, or in vitro transcribed nucleic acids with or without hydroxychloroquine (HCQ)...Suppression of innate activation preserved antigen expression, Spike-specific antibody titers, virus neutralization, and CD8⁺ T-cell responses following immunization with unmodified mRNA/LNPs or the clinically approved BNT162b2 vaccine...This strategy generalized across platforms, reducing cytokine responses induced by the adenoviral vector AZD1222 without affecting immunogenicity...Conclusion Across multiple platforms, including mRNA/LNPs, adenoviral vectors, AAV9-mediated CNS delivery, and genome editing, we show that dampening early inflammation reduces toxicity while preserving antigen expression, immune responses, and in vivo editing. These findings support a practical strategy to broaden the therapeutic window of nucleic acid-based medicines."

Preclinical • Hematological Disorders • Infectious Disease • Inflammation • Thrombocytopenia • CD8 • EPO • IFNG • IL6 • STING

Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study. (PubMed, Vaccine) - "Considering the magnitude, precision, and potential biases-such as selection bias due to informative censoring and potential outcome misclassification-the totality of evidence suggests a possible increased risk of TTS with post-AZD1222 vaccination that may be higher among subjects <60 years and 1-42 days after first AZD1222 dose, in line with the literature. Differential age distributions resulting from country-level differences in the risk minimisation measures may explain IRR disparities across data sources."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombocytopenia • Thrombosis